Andrew Reardon serves as the Chief Legal Officer and Secretary at Ligand Pharmaceuticals Inc., a position that underscores his significant expertise in the legal aspects of the biopharmaceutical industry. Prior to joining Ligand, Reardon amassed a wealth of experience in corporate law, focusing on intellectual property, mergers and acquisitions, and compliance. His career trajectory includes roles at several prominent law firms and biotech companies, where he honed his skills in navigating complex legal landscapes and ensuring regulatory adherence. Reardon's educational background is equally impressive, with a Juris Doctor from a top-tier law school and an undergraduate degree in biochemistry, providing him with a robust foundation to tackle the multifaceted challenges in the pharmaceutical sector. In his role at Ligand Pharmaceuticals, Reardon is instrumental in steering the company's legal strategy and safeguarding its intellectual assets. He plays a pivotal role in facilitating the company's growth through strategic acquisitions and partnerships, ensuring that all legal frameworks are meticulously crafted to support Ligand’s business objectives. Under his guidance, Ligand has successfully navigated numerous high-stakes negotiations and regulatory hurdles, cementing its position as a leader in the development and licensing of biopharmaceutical technologies. Reardon's leadership is characterized by his ability to balance rigorous legal oversight with a deep understanding of the scientific and commercial aspects of the industry, making him an invaluable asset to Ligand's executive team.